At #IMS25, Dr. Francesco Maura will present new research on the genomics that define neoplastic transformation in #multiplemyeloma precursor conditions. #mmsm 🗓️ Saturday, September 20 | 9:20 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social @szusmani.bsky.social

Coming up at #IMS25: Join MSK's Myeloma Service Chief @szusmani.bsky.social to learn about current challenges in #multiplemyeloma relapse & future research needed to overcome them. #mmsm 🗓️ Friday, September 19 | 9:40 a.m. EDT @mskcancercenter.bsky.social @myeloma-society.bsky.social

Coming up at #IMS25: Dr. Sham Mailankody will share the results of a phase 1 clinical trial of concurrent BCMA and GPRC5D #CARTcells for relapsed/refractory #multiplemyeloma. 🗓️ Thursday, September 18 | 4:40 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

At #IMS25, Dr. Carlyn Tan will share new data on early mortality associated with real-world bispecific antibody therapy for relapsed/refractory #multiplemyeloma. 🗓️ Wednesday, September 17 | 12:14 p.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK experts have arrived at #IMS25! Join Dr. Francesco Maura to learn about genomic drivers of resistance to anti-BCMA immunotherapies in #multiplemyeloma. #mmsm 🗓️ Wednesday, September 17 | 11:10 a.m. EDT @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

MSK is headed to Toronto for #IMS25! Stay tuned for posters and presentations that are advancing #multiplemyeloma research and treatments. #mmsm @mskcancercenter.bsky.social @szusmani.bsky.social @myeloma-society.bsky.social

Starting TODAY! Join @greatdebates.bsky.social and Yelena Janjigian, Chief of the MSK Gastrointestinal Oncology Service, to learn about the latest treatments for #gastriccancer and #colorectalcancer. @mskcancercenter.bsky.social #crcsm #GIcancer See the full agenda 📖: bit.ly/48g13pf

🚨 Happening Soon: @mskcancercenter.bsky.social's Eileen O'Reilly and @mayocliniccancer.bsky.social's Tanios Bekaii-Saab will kick off #ISGIO2025! Join them for opening remarks as program chairs at 9 a.m. CDT/10 a.m. EDT. #GICSM See the agenda for a full lineup of MSK experts: bit.ly/3JSTg6V

Happening Tuesday, 9/9 at #WCLC25: MSK's Dr. Alexis Chidi will discuss how deep learning-based CT analysis enhances #lungcancer risk prediction in never smoking women. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social Tuesday, 9/9 | 10 a.m. CEST More: bit.ly/45XeCZq

Happening Tuesday, 9/9 at #WCLC25: MSK's Dr. David Jones will discuss perioperative modalities for resectable non small cell #lungcancer. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social l Tuesday, 9/9 | 1 p.m. CEST Learn more: bit.ly/3V3O8iD

We're counting down the days until #ASH25 in December! ⏰Don't miss the scientific workshops taking place on the Friday before the meeting. @ash.hematology.org @mskcancercenter.bsky.social

At #WCLC25, our #RadOnc colleague Jennifer Ma will present a retrospective review of intrathoracic radiotherapy to treat #HPV-associated head and neck #squamouscellcarcinoma metastases. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social September 9 | 3 p.m. CEST ➡️ bit.ly/4mUWZ2m

Tomorrow morning, #lungcancer expert Mark Kris will discuss clinicopathologic features of TP53/RB1-mutant squamous cell lung cancers at #WCLC25. #LCSM @iaslc.bsky.social @mskcancercenter.bsky.social September 8 | 10:30 a.m.. CEST ➡️ bit.ly/41EZM7b

Coming up at #WCLC25: @mskcancercenter.bsky.social's Helena Yu will highlight diagnostic and treatment opportunities for #leptomeningealdisease in oncogene-driven non-small cell #lungcancer. #LCSM @iaslc.bsky.social September 7 | 3:53 p.m. CEST ➡️ bit.ly/4mOHBnV

Don't miss an opportunity to learn from the Chief of the Thoracic Oncology Service at @mskcancercenter.bsky.social! At #WCLC25, Mark Awad will share lessons about work-life balance in high-stress medical careers. #LCSM @iaslc.bsky.social September 7 | 1:45 p.m. CEST ➡️ bit.ly/3HTNpxr

Happening Monday, 9/8 at #WCLC25: MSK pathologist Dr. Natasha Rekhtman will discuss optimizing front-line treatment for small cell #lung cancer. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social 📆: September 8 at 5 p.m. CEST Learn more: bit.ly/4mXBiig

Out now in @cp-trendsbiochem.bsky.social: "PTMs as Molecular Encoders: Reprogramming Chaperones into Epichaperomes for Network Control in Disease" from @chiosislabmskcc.bsky.social. Learn more ⬇️

Happening tomorrow at #WCLC25: @mskcancercenter.bsky.social's @charlesrudin.bsky.social will highlight future directions in small cell #lungcancer research. Follow along for coverage of the latest advances. #LCSM #SCLC @iaslc.bsky.social September 6 | 10:30 a.m. CEST ➡️ bit.ly/3HJJmnp

At MSK, Clinical Nurse Specialists (CNS) are making a significant impact on patient outcomes through their expert guidance, evidence-based interventions, & compassionate leadership. This #CNSWeek, we honor their dedication to advancing care and improving lives. Help celebrate our MSK CNSs below! 🎉

Results of a pilot study led by investigators at @mskcancercenter.bsky.social showed that interleukin-18 “armored” CAR T cells targeting CD371 were effective at treating relapsed/refractory acute myeloid #leukemia at low doses. @markgeyermd.bsky.social Learn more: bit.ly/4mFwo9q

Congrats to Rastko Rakočević of the Pulmonary Service on receiving a certificate of excellence for presenting a top abstract in a plenary session at #AABIP2025! He presented research on robotic-assisted #bronchoscopy for biopsy of primary #lungcancers. @mskcancercenter.bsky.social

Breast medical oncologist and early drug development specialist @breastcancerdoc.bsky.social discusses how molecular subtyping, antibody-drug conjugates, and precision trials are reshaping the field of #breastcancer on @emjreviews.bsky.social lastest podcast. 🎙️ Listen here: bit.ly/422CWXd

www.youtube.com/watch?v=7JOT... Found this great video of #DrMichaelPostow explaining potential of predicting #immunotherapy response with imaging! @mskcancercenter.bsky.social #ShortTakesInOncology #peer2peermd

New FDA-approved blood test "Shield" offers a less invasive #colorectal cancer screening, but while Shield may detect later-stage cancers, it misses over one-third of stage 1 cancers and most precancerous polyps. Learn more about what MSK experts have to say about Shield. ⬇️ #cansky

Introducing a new, high-yield CME program @mskcancercenter.bsky.social designed to streamline preparation for the ABIM certification & recertification exams in Medical Oncology. Registration is complimentary for all fellows. Learn more: bit.ly/MedOncReview2025 #MSKAcceleratedMedOncReview

Allison Gordon and colleagues evaluated the effectiveness of dupilumab in place of steroids for people who experienced adverse skin reactions caused by antibody-drug conjugates. @mskcancercenter.bsky.social Read the study: bit.ly/4mI1A7p

New research from MSK develops a powerful new resource for studying #generegulation across #eukaryotes; uncovers how “jumping genes” can drive #cancer growth; describes how an unexpected oxygen sensor regulates #ferroptosis; and more.

Among much speculation about the potential applications of #artificialintelligence in research, it's great to see @mskcancercenter.bsky.social experts provide guidance on responsible and practical uses of AI in #oncology. #cancerresearch www.nature.com/articles/s41...

🎉 We have some wonderful news to share! MSK is ranked #2 in the nation for cancer care and #1 for urology care according to the @usnews.com 2025-2026 Best Hospitals list. Learn more: bit.ly/3UC4puE

🎉 Congratulations to MSK's most recent Awards & Appointments honorees, including MSK being ranked the Best Cancer Center in the Northeast and First in the Nation for Urology Care by @usnews.com, and more: www.mskcc.org/news-release...

A new study from Anthony Yu, Chau Dang, and Jennifer Liu evaluated the cardiac safety of reduced cardiotoxicity surveillance during HER2-targeted treatment. @mskcancercenter.bsky.social @jaccjournals.bsky.social www.jacc.org/doi/10.1016/...

“When choosing cancer therapies, people should not have to choose between being alive & living”   Toxicity minimizing language ("safe” & “tolerable”) are subjective & can downplay QOL limiting side effects from treatment. 🚨New @ascocancer.bsky.social Podcast is live today! @coffeemommy.bsky.social

MSK researchers are advancing the standard of care for treating head and neck cancers, including #thyroidcancer. Recent work highlights progress in areas such as active surveillance, identification of mutation profiles, #redifferentiation therapy, and more.

🚨 New research led by MSK's Dr. Andrew McPherson, Dr. Sohrab Shah, & team reveals how whole-genome doubling (WGD) helps #ovariancancer tumors evade treatment and suppress the immune system. The study, which was published in @nature.com, found that over 65% of ovarian cancer tumors showed high #WGD.

New research from MSK investigates whether introducing new mutations could make #immunotherapy more effective against some cancers; shows that people in their 90s who underwent #lungcancer surgery had positive outcomes; shares lessons on the responsible governance of #AI in oncology; and more ⬇️

Just out in @astct.bsky.social: Updated allogeneic stem cell donor selection guidelines from the CIBMTR/NMDP. Kudos to @mskcancercenter.bsky.social's Brian Shaffer and team! #stemcelltransplant #Cancer www.sciencedirect.com/science/arti...

Happening now at #ESMOGI25: Recent @mskcancercenter.bsky.social fellow Layal Al Mahmasani is presenting two posters that advance our understanding of #biliarytractcancers and IDH2-mutated #cholangiocarcinoma. Learn more: bit.ly/3I9QadI

This morning at #ESMOGI25, medical oncologist Eileen O'Reilly weighed in on the implications of molecular testing for people being treated for #pancreaticcancer. @mskcancercenter.bsky.social

New research from MSK finds improving intestinal metabolism may help treat chronic #inflammation and prevent cancer; shows how #breastcancer resistance is linked to #APOBEC3 enzymes; and more.

On June 2, we welcomed our 2025 summer interns under CBSP (#compbio), ChBSP (#ChemBio), EISP (#Engineering #imaging), MBSP (#MechanisticBiology) & MSK Engage programs. We are thrilled to host them!

The #ASCOEdBook 2025 collection is now complete. Check out the full edition: bit.ly/44bvEkk

Great honor to accept the teaching award from the @mskcancercenter.bsky.social @mskdeptofmed.bsky.social H/O fellows on behalf of my colleagues of the Adult BMT Service

The 2025 @icmlugano.bsky.social conference is off to the races! @mskcancercenter.bsky.social faculty contributed multiple abstracts, including senior research scientist and hematologist Alfredo Rivas Delgado's study on the mutation landscape of B-cell lymphomas. Learn more: bit.ly/3HYs1qe

At the European Hematology Association Annual Meeting, #lymphoma specialist Lorenzo Falchi, MD, presented a study that found epcoritamab plus lenalidomide and rituximab achieved high response rates & survival benefits compared w/ usual care in relapsed/refractory #follicularlymphoma. bit.ly/3STk1cs

Melanoma oncologist Dr. Michael Postow leads a conversation and Q&A on the latest #melanoma cancer research at #ASCO25. @ascocancer.bsky.social

Congratulations to cellular therapist Dr. Heather Landau on sharing positive results from her phase 1 clinical trial on chimeric antigen receptor #CART cell therapy for patients with AL amyloidosis. #ASCO25 @ascocancer.bsky.social

🚨New from @ascocancer.bsky.social: MSK cellular therapist Dr. Heather Landau shared dramatic results from a phase 1 clinical trial showing that a chimeric antigen receptor (CAR) T cell therapy appears to be effective at stopping AL amyloidosis in patients. bit.ly/4dPiZrC

Dr. Violaine Randrian, a visiting investigator at MSK, spoke about a study that evaluated gene-specific outcomes in individuals with #lynchsyndrome treated with immune checkpoint blockade for advanced #cancer at #ASCO25.

At @ascocancer.bsky.social, scientists from MSK presented promising results on three different targeted therapies — one for small cell #lungcancer and two for non-small cell lung cancer. Read more from Dr. Charles Rudin, Dr. Helena Yu, and Dr. Jamie Chaft: bit.ly/43JDEZF #ASCO25

This morning at #ASCO25, Melanoma Service Chief Michael Postow, MD, is chairing a session with leading #melanoma experts to share the latest research and treatment findings. #skincancer @mskcancercenter.bsky.social ‪@ascocancer.bsky.social‬ Learn more: bit.ly/43VMNzn